← Pharmacy curriculum
Module 6910 lessonsDAST IV lecture, RxPrep foundations, current endocrine guidance, NIH references, FDA labeling, and DailyMed

Gonadal Hormone Pharmacology

Trace gonadal hormones from hypothalamic signaling through tissue response, then use that physiology to interpret hypogonadism, hormone replacement, safety monitoring, and pathway-directed therapy.

01

Explain how pulsatile GnRH, LH, FSH, inhibin, and sex steroids regulate the hypothalamic-pituitary-gonadal axis.

02

Connect Leydig and Sertoli cell function to testosterone production, spermatogenesis, and the laboratory pattern of gonadal failure.

03

Apply the two-cell, two-gonadotropin model to follicular development, ovulation, luteal physiology, and menstrual-cycle feedback.

04

Trace cholesterol through testosterone, dihydrotestosterone, estradiol, and progesterone pathways and identify the enzymes that create tissue-specific effects.

05

Compare androgen, estrogen, and progesterone receptor signaling and explain why tissue context changes the response to a ligand.

06

Diagnose male hypogonadism only when compatible findings and repeat accurate morning testosterone measurements agree.

07

Select and counsel on testosterone formulations using route, kinetics, adherence, exposure risk, fertility goals, and patient preference.

08

Monitor testosterone therapy for therapeutic response, erythrocytosis, blood pressure, prostate concerns, edema, sleep apnea, and misuse.

09

Describe the pharmacologic foundations of estrogen and progestogen therapy without substituting this overview for condition-specific prescribing.

10

Distinguish the initial flare and delayed suppression of GnRH agonists from the direct suppression produced by GnRH antagonists.

69.01

The HPG Axis and Pulsatile Control

The reproductive axis converts a pulse pattern from the hypothalamus into gonadal steroid production, gametogenesis, and feedback that changes across age, sex, and physiologic state.

What to learn
  • Pulsatile GnRH
  • LH and FSH
  • Negative feedback
  • Positive feedback
  • Inhibin
Signal controlFollow the pulse from hypothalamus to gonad
01PulseHypothalamic GnRH

Intermittent signaling preserves pituitary response

02RelayPituitary LH and FSH

Gonadotropins distribute steroidogenic and gametogenic work

03FeedbackSteroids and inhibin

Downstream hormones reshape the next signal

Preserve the pulse

Physiologic GnRH is released in pulses. Continuous receptor stimulation eventually suppresses pituitary gonadotropin secretion, while pulse timing and amplitude help shape LH and FSH output.

Read the feedback loop

Testosterone, estradiol, progesterone, and inhibin feed back to the hypothalamus and pituitary. Most sex-steroid feedback is negative, but sustained estradiol near mid-cycle can produce positive feedback and the LH surge.

Interpret values as a set

A single gonadal hormone value is rarely enough. Symptoms, biologic timing, binding proteins, LH, FSH, prolactin, pregnancy status when relevant, and the clinical context determine what the value means.

0 of 1 answered
01What happens when a GnRH agonist is given continuously after the initial stimulation phase?
Answer every question to submit.
69.02

Testicular Steroidogenesis and Spermatogenesis

Testicular function depends on coordinated LH action in Leydig cells, FSH action in Sertoli cells, high intratesticular testosterone, and intact seminiferous architecture.

What to learn
  • Leydig cells
  • Sertoli cells
  • Intratesticular testosterone
  • Spermatogenesis
  • Inhibin B
Testicular mapSeparate androgen production from sperm support
01LHLeydig cell

Generate testosterone from cholesterol-derived precursors

02FSHSertoli cell

Support germ cells and produce inhibin B

03LocalIntratesticular testosterone

Maintain the concentration required for spermatogenesis

Generate testosterone

LH activates its receptor on Leydig cells and supports cholesterol transport and steroidogenesis. Testosterone then acts locally and systemically and contributes negative feedback at the hypothalamus and pituitary.

Support germ cells

FSH acts on Sertoli cells, which support germ-cell development, produce inhibin B, and help maintain the specialized environment required for spermatogenesis.

Protect fertility logic

Exogenous testosterone suppresses LH and FSH. Serum testosterone may normalize while intratesticular testosterone and sperm production fall, so fertility goals must be discussed before therapy begins.

0 of 1 answered
01Why can testosterone replacement reduce sperm production even when serum testosterone improves?
Answer every question to submit.
69.03

Ovarian Steroidogenesis and Cycle Feedback

The ovarian cycle emerges from coordinated theca and granulosa cell function, follicular recruitment, estradiol feedback, ovulation, and corpus luteum progesterone production.

What to learn
  • Two-cell model
  • Follicular phase
  • LH surge
  • Corpus luteum
  • Luteal phase
Cycle physiologyBuild the follicle through two coordinated cells
01ThecaLH creates androgen substrate

Supply precursor to the neighboring granulosa cell

02GranulosaFSH increases aromatase

Convert androgen substrate to estradiol

03LutealCorpus luteum produces progesterone

Transform and stabilize the post-ovulatory endometrium

Build estradiol

LH stimulates theca cells to produce androgen substrate. FSH increases granulosa-cell aromatase, which converts that substrate to estradiol. This is the two-cell, two-gonadotropin model.

Trigger ovulation

Rising estradiol usually suppresses gonadotropins, but sustained high estradiol from the dominant follicle switches to positive feedback and generates the mid-cycle LH surge.

Maintain the luteal phase

After ovulation, the corpus luteum produces progesterone and estradiol. Progesterone converts the proliferative endometrium toward a secretory state and suppresses another ovulatory surge.

0 of 1 answered
01Which pairing correctly describes ovarian estradiol synthesis?
Answer every question to submit.
69.04

Steroidogenesis and Local Hormone Metabolism

Sex steroids share a cholesterol-derived pathway, but enzyme expression in gonads and peripheral tissues determines which active hormone reaches each receptor.

What to learn
  • Cholesterol
  • StAR
  • CYP11A1
  • 5-alpha-reductase
  • Aromatase
Steroid pathwayTrace shared precursors into tissue-specific products
01EnterCholesterol through StAR

CYP11A1 creates pregnenolone

02BuildAndrogen and progestogen pathways

Tissue enzymes determine the dominant product

03ConvertDHT or estradiol

5-alpha-reductase and aromatase modify local action

Enter the steroid pathway

StAR moves cholesterol into the mitochondrial environment where CYP11A1 creates pregnenolone. Downstream enzymes then generate progestogens, androgens, and estrogens.

Create testosterone

Leydig-cell pathways convert steroid precursors through androstenedione, with HSD17B3 supporting testosterone formation. The exact pathway depends on tissue enzyme expression.

Modify action locally

5-alpha-reductase converts testosterone to the more potent androgen DHT in selected tissues. Aromatase converts androgen substrate to estrogen, making local metabolism part of the final pharmacologic response.

0 of 1 answered
01Which enzyme converts testosterone to dihydrotestosterone?
Answer every question to submit.
69.05

Sex Steroid Receptors and Tissue Response

Androgen, estrogen, and progesterone receptors are ligand-regulated transcription factors whose effects depend on receptor distribution, co-regulators, chromatin, dose, and duration.

What to learn
  • Androgen receptor
  • Estrogen receptor alpha
  • Estrogen receptor beta
  • Progesterone receptor
  • Selective receptor modulation
Receptor contextThe ligand starts the signal, but the tissue writes the response
01BindAR, ER, or PR

Ligand changes receptor conformation

02RecruitCo-regulators

Cell-specific proteins amplify or restrain transcription

03ExpressTissue response

Bone, breast, endometrium, brain, and liver can diverge

Activate nuclear signaling

A steroid enters the cell, binds its receptor, changes receptor conformation, and alters transcription at hormone-response elements or through other transcriptional partners.

Respect tissue context

Receptor subtype, co-activator and co-repressor expression, local hormone metabolism, and baseline gene programs determine whether a tissue response is strong, weak, or qualitatively different.

Understand selective modulators

A selective estrogen receptor modulator can act as an agonist in one tissue and an antagonist in another because the ligand-bound receptor recruits a different regulatory complex.

0 of 1 answered
01Why can a selective estrogen receptor modulator protect bone without stimulating every estrogen-responsive tissue equally?
Answer every question to submit.
69.06

Diagnosing and Classifying Hypogonadism

Hypogonadism is a clinical and biochemical diagnosis, not a symptom label or a single low laboratory result.

What to learn
  • Compatible symptoms
  • Repeat morning testosterone
  • Accurate assay
  • Primary failure
  • Secondary failure
Diagnostic logicConfirm the deficit, then locate the failure
01AgreeSymptoms plus valid laboratory evidence

Do not diagnose from a nonspecific symptom alone

02RepeatAccurate morning testosterone

Exclude transient illness and invalid timing

03LocateLH and FSH

Separate primary gonadal from central signaling failure

Require agreement

In men, diagnosis requires compatible symptoms or signs plus unequivocally and consistently low testosterone measured with an accurate assay. A low result should generally be repeated in the morning under appropriate conditions.

Locate the level

Low testosterone with elevated LH and FSH supports primary testicular failure. Low testosterone with low or inappropriately normal gonadotropins supports central disease and may require prolactin measurement or pituitary evaluation.

Find reversible contributors

Acute illness, obesity, sleep disruption, opioid or glucocorticoid exposure, nutritional stress, and selected systemic disorders can lower testosterone. Treating the context may be more appropriate than immediate replacement.

0 of 1 answered
01A man has fatigue and one low afternoon testosterone result during acute illness. What is the best next step?
Answer every question to submit.
69.07

Testosterone Formulations and Exposure

Testosterone products differ in absorption, peak-to-trough variation, administration burden, transfer risk, food requirements, injection interval, and ease of dose adjustment.

What to learn
  • Topical gel
  • Transdermal system
  • Intramuscular ester
  • Subcutaneous ester
  • Oral undecanoate
Product selectionMatch route and kinetics to the person
01DailyTopical exposure

Flexible adjustment with transfer precautions

02DepotIM or SC ester

Longer intervals with product-specific peaks and monitoring

03OralTestosterone undecanoate

Follow formulation-specific administration and blood-pressure guidance

Compare routes

Topical products provide daily exposure and easier dose adjustment but can transfer to others. Injectable esters may simplify adherence but can produce product-specific peak and trough patterns. Oral testosterone undecanoate has formulation-specific administration and monitoring requirements.

Use product instructions

Application site, skin contact precautions, injection technique, timing of serum measurement, meal instructions, and dose-adjustment rules differ by product. One testosterone label cannot safely stand in for another.

Prevent secondary exposure

Patients using topical testosterone should wash hands after application, cover the site after drying, and prevent skin contact with others until the product-specific precautions have been followed.

0 of 1 answered
01Which counseling point is most important for testosterone gel?
Answer every question to submit.
69.08

Testosterone Monitoring, Safety, and Fertility

Safe testosterone therapy pairs symptom response with surveillance for erythrocytosis, blood-pressure elevation, prostate concerns, edema, sleep apnea, thromboembolic symptoms, and misuse.

What to learn
  • Hematocrit
  • Blood pressure
  • PSA
  • Fertility
  • Misuse
Monitoring loopMeasure benefit and toxicity together
01RespondSymptoms and testosterone

Confirm appropriate product-specific exposure

02ProtectHematocrit and blood pressure

Detect erythrocytosis and pressure elevation

03ReassessProstate, fertility, edema, apnea, misuse

Investigate new risk rather than escalating automatically

Monitor exposure

Assess clinical response, adherence, serum testosterone at the product-specific time, hematocrit, and blood pressure. Product labeling and patient risk determine the exact interval and additional tests.

Respond to safety signals

A marked hematocrit rise, new venous thromboembolic symptoms, uncontrolled blood pressure, worsening edema, severe sleep-apnea concerns, or a clinically important prostate finding requires reassessment.

Protect reproductive goals

Testosterone should not be started when near-term fertility is desired because gonadotropin suppression can reduce sperm production. An alternate reproductive evaluation and treatment pathway is needed.

0 of 1 answered
01Which baseline goal most directly argues against starting testosterone replacement?
Answer every question to submit.
69.09

Estrogen and Progestogen Pharmacology Foundations

Estrogens and progestogens differ by molecule and route, but their major clinical effects follow receptor biology, hepatic exposure, endometrial context, and patient-specific thrombotic or cancer risk.

What to learn
  • Estradiol
  • Ethinyl estradiol
  • Progesterone
  • Progestins
  • Endometrial protection
Hormone contextMolecule, route, and tissue determine the clinical result
01EstrogenProliferation and systemic effects

Support target tissues while accounting for hepatic and thrombotic context

02ProgestogenSecretory transformation

Oppose persistent endometrial estrogen exposure when needed

03SelectIndication-specific regimen

Contraception, menopause, and gynecologic care require separate risk frameworks

Distinguish molecules and routes

Estradiol, conjugated estrogens, ethinyl estradiol, micronized progesterone, and synthetic progestins have different potency, metabolism, receptor profiles, and route-dependent effects. They should not be treated as a single interchangeable class.

Connect physiology to therapy

Estrogen supports endometrial proliferation, bone, urogenital tissue, and multiple systemic functions. Progesterone transforms the estrogen-primed endometrium and supports the luteal reproductive state.

Frame safety correctly

Risk depends on indication, dose, route, duration, age, uterus status, thrombotic history, cancer history, and other comorbidities. Detailed selection belongs in the relevant condition-specific module.

0 of 1 answered
01Why is a progestogen often paired with systemic estrogen in a patient with an intact uterus?
Answer every question to submit.
69.10

GnRH Modulation and Pathway-Directed Therapy

Gonadal hormone pathways can be altered at the hypothalamic-pituitary signal, steroid-synthesis enzymes, local conversion enzymes, or the final receptor.

What to learn
  • GnRH agonist
  • GnRH antagonist
  • Aromatase inhibitor
  • 5-alpha-reductase inhibitor
  • Receptor antagonist
Intervention pointsChoose where to alter the hormone pathway
01SignalGnRH agonist or antagonist

Change pituitary gonadotropin output

02SynthesizeAromatase or 5-alpha-reductase

Reduce formation of an active tissue hormone

03RespondReceptor modulator or antagonist

Change tissue action after the hormone is produced

Differentiate GnRH strategies

Continuous GnRH agonist therapy initially increases LH, FSH, and gonadal steroids before receptor desensitization produces suppression. GnRH antagonists block the receptor directly and suppress gonadotropins without the agonist flare.

Block hormone production

Aromatase inhibitors reduce estrogen synthesis, 5-alpha-reductase inhibitors reduce DHT formation, and selected steroidogenesis inhibitors reduce androgen output at earlier enzymatic steps.

Block hormone action

Estrogen, progesterone, and androgen receptor antagonists or selective modulators change tissue response without necessarily eliminating hormone production. Their clinical use and safety depend on indication and tissue context.

0 of 1 answered
01Which approach suppresses LH and FSH without an initial gonadal-steroid flare?
Answer every question to submit.

Check the connections.

Each attempt draws 10 questions from the complete 100 question bank.

100 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

PharmacyOpen tools